Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07308314

Taining Golden Lake Comprehensive Chronic Disease Management Initiative

This study aims to establish the first county-level, population-based prospective cohort in Taining County, Fujian Province, China. The cohort will include at least 20,000 residents aged 18 years or older. The project will systematically collect questionnaires, physical measurements, laboratory tests, imaging data, and biological samples to build a multi-dimensional health database and biobank. Through 3-year follow-up, the study seeks to reveal the epidemiological patterns and risk factors of chronic diseases, characterize the natural course of multimorbidity and aging syndromes, and develop a comprehensive chronic disease management model suitable for rural and mountainous regions.

Recruiting

Interested in participating?

Request Info

Key information

About this study

China is undergoing rapid population aging, with chronic non-communicable diseases (NCDs) becoming the leading cause of death and disability. Taining County, located in a mountainous area of Fujian Province, faces a higher-than-average aging population and a growing burden of hypertension, diabetes, dyslipidemia, and cardiovascular diseases. Early detection and standardized management remain insufficient, and healthcare resources are limited. This study will establish a prospective cohort covering ≥20,000 residents, integrating demographic, lifestyle, clinical, laboratory, and imaging data. Active follow-up will be conducted annually, complemented by passive follow-up through local healthcare and death registry systems. The study will (1) identify epidemiological features and risk factors of common chronic diseases, (2) explore multimorbidity and aging trajectories, and (3) develop a replicable "Taining Model" for chronic disease prevention and management at the county level. The results will provide an evidence base for public health decision-making and chronic disease control strategies in similar rural and mountainous regions.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age ≥18 years, male or female.
  • Resident of Taining County for ≥6 months and expected to remain in the county for at least the next 3 years.
  • Full civil capacity and able to understand study procedures.
  • Willing to voluntarily participate and provide written informed consent.
  • Able to complete baseline survey and follow-up visits.

Exclusion criteria

  • Refusal to sign informed consent.
  • Severe psychiatric disorders or cognitive impairment preventing participation.
  • End-stage disease with expected survival <1 year.
  • Long-term migrants (≥6 months per year outside the county), unable to guarantee follow-up.
  • Participation in other clinical studies that may interfere with this research.

Treatment and study plan

Primary outcomes

  1. Incidence of Major Adverse Cardiovascular Events (MACE)

    Time frame: Up to 36 months

    Composite outcome including cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke. Events will be ascertained through active follow-up and confirmed using medical records and hospital discharge summaries.

Secondary outcomes

  1. Incidence of Cardiovascular and Cerebrovascular Events

    Time frame: Up to 36 months

    New onset of coronary heart disease, stroke, or heart failure, identified through follow-up visits and confirmed using medical records.

  2. Heart Failure-Related Rehospitalization Rate

    Time frame: Up to 36 months

    Rehospitalization due to worsening heart failure among participants diagnosed with heart failure, confirmed by hospital admission records.

  3. Bleeding Events

    Time frame: Up to 36 months

    Occurrence of clinically significant bleeding events, including gastrointestinal bleeding and other major or clinically relevant non-major bleeding, identified through follow-up and medical records.

  4. Health Economics Outcomes

    Time frame: Up to 36 months

    Direct medical costs, hospitalization expenses, outpatient visit costs, medication costs, and health service utilization related to chronic disease management, collected from medical records and insurance data.

  5. Cognitive Function Outcomes

    Time frame: Baseline and annual follow-up (Year 1-3)

    Changes in cognitive function assessed using standardized cognitive screening tools administered at baseline and during follow-up.

  6. Cancer Incidence and Cancer-Related Outcomes

    Time frame: Up to 36 months

    Newly diagnosed malignant tumors and cancer-related outcomes, identified through self-report and confirmed by medical records or cancer registry data.

  7. All-Cause Mortality

    Time frame: Up to 36 months

    Death from any cause, confirmed through medical records and the local death registry system.

Study contacts

Contact information is provided by the study sponsor or research team.

Dajun Chai, MD

CONTACT

[email protected]

0086059187981637

Hailin Zhang

CONTACT

[email protected]

0086059187981637

Sponsors and collaborators

Lead sponsor

First Affiliated Hospital of Fujian Medical University

Other

Registry information

Acronym: TAIGOLD-CDM

Important dates

Study start
2025
Primary completion
2027
Study completion
2028
First posted
Dec 29, 2025
Registry last updated
Dec 29, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.